Humana stock unchanged as UBS reiterates Neutral rating after court ruling

Humana (NYSE:HUM) experienced a legal setback as a US District Court dismissed its lawsuit against the Department of Health and Human Services regarding Medicare Advantage star ratings, citing premature filing. This ruling is projected to significantly reduce Humana's Medicare Advantage members in 4-star or higher plans from 94% to 25% by 2025, with some analysts forecasting potential earnings headwinds of $2-3 billion. However, firms like UBS, Barclays, and Morgan Stanley noted that these potential losses were largely factored into Humana's 2026 bids and earnings projections, and Humana retains the option to refile or appeal the case after exhausting administrative remedies.

Analysis

Humana Inc. (HUM) faces a significant operational and financial headwind following the dismissal of its lawsuit against the U.S. Department of Health and Human Services. The court's decision, based on a procedural failure to exhaust administrative remedies, is projected to cause a severe decline in its Medicare Advantage (MA) plan quality, with the percentage of members in plans rated four stars or higher dropping from 94% in 2024 to an estimated 25% in 2025. This downgrade carries substantial financial implications, with analysts from Guggenheim and Raymond James forecasting a potential earnings impact of $2-3 billion and $15 per share, respectively. However, the market impact appears partially mitigated, as several investment banks, including UBS, Barclays, and Morgan Stanley, noted that this negative outcome was largely anticipated and factored into Humana's 2026 MA bids and existing financial models. Consequently, UBS has maintained its Neutral rating and $285 price target. While the company is trading near its 52-week low, some analysts remain optimistic about a long-term recovery in star ratings by 2027-2028, and Humana retains the option to refile or appeal the case.

Key Decisions for Investors

• Investors should assess whether the stock's trading level near its 52-week low fully incorporates the projected $2-3 billion earnings headwind from the Medicare Advantage star rating downgrade.
• Consider the long-term recovery thesis, as some analysts project a rebound in star ratings by 2027-2028, which could present a value opportunity for investors with a multi-year horizon.
• Monitor for any company announcements regarding a decision to appeal or refile the lawsuit, as a successful legal challenge would serve as a significant positive catalyst for the shares.